Tech Center 1600 • Art Units: 1634 1682
This examiner grants 42% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18568366 | DETECTING METHYLCYTOSINE USING A MODIFIED BASE OPPOSITE TO THE METHYLCYTOSINE | Non-Final OA | ILLUMINA, INC. |
| 17185730 | KITS FOR GENOTYPING | Final Rejection | ILLUMINA, INC. |
| 18050855 | METHODS AND SYSTEMS FOR IMPROVING PATIENT MONITORING AFTER SURGERY | Non-Final OA | GUARDANT HEALTH, INC. |
| 17489677 | METHODS AND SYSTEMS TO IMPROVE THE SIGNAL TO NOISE RATIO OF DNA METHYLATION PARTITIONING ASSAYS | Non-Final OA | GUARDANT HEALTH, INC. |
| 18174491 | BREAST CANCER-RESPONSE PREDICTION SUBTYPES | Non-Final OA | The Regents of The University of California |
| 18563676 | LINKED AMPLIFICATION TETHERED WITH EXPONENTIAL RADIANCE | Non-Final OA | CALIFORNIA INSTITUTE OF TECHNOLOGY |
| 17924765 | METHODS OF DETECTING THE EFFICACY OF ANTICANCER AGENTS | Final Rejection | Georgia Tech Research Corporation |
| 18152346 | Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18381126 | Markers of Triple-Negative Breast Cancer and Uses Thereof | Final Rejection | Vanderbilt University |
| 17634217 | METHOD FOR ALTERING THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS BASED ON ANALYSIS OF ctDNA | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | Final Rejection | Board of Regents, The University of Texas System |
| 18261091 | LAYERED ANALYSIS OF METHYLATED BIOMARKERS FOR USE IN CANCER DIAGNOSIS AND PROGNOSIS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17613892 | METHODS AND COMPOSITIONS FOR MULTIPLE-PARAMETER SINGLE-CELL ANALYSIS USING SPECTRALLY ENCODED MICROBEADS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 16848989 | NONINVASIVE DIAGNOSTICS BY SEQUENCING 5-HYDROXYMETHYLATED CELL-FREE DNA | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18023598 | PREDICTION OF A RESPONSE OF A PROSTATE CANCER SUBJECT TO THERAPY OR PERSONALIZATION OF THERAPY OF A PROSTATE CANCER SUBJECT | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | Non-Final OA | William Marsh Rice University |
| 18261874 | METHODS FOR DETECTING utDNA | Non-Final OA | Washington University |
| 16309271 | COMPOSITIONS AND METHODS FOR DETECTION OF NUCLEIC ACID MUTATIONS | Final Rejection | Natera, Inc. |
| 17810823 | METHOD FOR DIAGNOSING COLORECTAL CANCER BY DETECTING INTRAGENIC METHYLATION | Final Rejection | Industry-Academic Cooperation Foundation, Yonsei University |
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | Non-Final OA | EG BIOMED CO., LTD. |
| 17997490 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF COLORECTAL CANCER | Non-Final OA | EG BIOMED CO., LTD. |
| 18562953 | An Isothermal Diagnostic Test that Utilizes a Cas Protein and a Polymerase | Non-Final OA | New England Biolabs, Inc. |
| 18009013 | METHODS OF DETECTING METHYLATED CpG | Final Rejection | Ramot at Tel-Aviv University Ltd. |
| 17587963 | DETECTING THE PRESENCE OR ABSENCE OF MULTIPLE TYPES OF CANCER | Final Rejection | Exact Sciences Corporation |
| 18894793 | METHOD FOR IDENTIFYING TARGETS FOR PRECISION CANCER THERAPY | Non-Final OA | Tampere University Foundation Sr |
| 18269171 | SELECTIVE LYSIS OF HUMAN BLOOD CELLS | Non-Final OA | Roche Molecular Systems, Inc. |
| 18153615 | COMPOSITIONS AND METHODS FOR DETECTION OF CANDIDA AURIS | Final Rejection | Roche Molecular Systems, Inc. |
| 17961200 | MULTIPLEX PCR DETECTION OF ALK, RET, AND ROS FUSIONS | Final Rejection | Roche Molecular Systems, Inc. |
| 18540517 | BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17816214 | COMPOSITIONS AND METHODS FOR ASSESSING IMMUNE RESPONSE | Non-Final OA | Life Technologies Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy